SCHEMBL6284416

SCHEMBL6284416

Cc1cc(N)n(-c2ccc(F)cc2)n1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.68
CYP2C19 P33261 3/20 0.68
MAPK1 P28482 2/20 0.68
LMNA P02545 4/20 0.65
SMN1; SMN2 Q16637 5/20 0.62
RAB9A P51151 5/20 0.62
MEN1 O00255 4/20 0.62
KMT2A Q03164 4/20 0.62
NPC1 O15118 4/20 0.62
ALDH1A1 P00352 3/20 0.62
POLB P06746 2/20 0.59
CYP3A4 P08684 2/20 0.58
CYP2C9 P11712 2/20 0.58
PKM P14618 1/20 0.52
PTGS1 P23219 1/20 0.51
MAPT P10636 3/20 0.49
TP53 P04637 1/20 0.49
L3MBTL1 Q9Y468 2/20 0.47
HTT P42858 1/20 0.47
RECQL P46063 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL224624 0.85 CYP1A2 (0.72) CYP1A2CYP2C19MAPK1LMNASMN1; SMN2
SCHEMBL8864119 0.85 CYP1A2 (0.72) CYP1A2CYP2C19MAPK1LMNASMN1; SMN2
SCHEMBL18692973 0.83 POLB (0.67) CYP1A2CYP2C19MAPK1LMNASMN1; SMN2
SCHEMBL18692285 0.82 MEN1 (0.63) CYP1A2CYP2C19MAPK1LMNASMN1; SMN2
SCHEMBL20413703 0.81 CYP1A2 (0.68) CYP1A2CYP2C19MAPK1LMNASMN1; SMN2
SCHEMBL11748979 0.81 CYP1A2 (0.68) CYP1A2CYP2C19MAPK1LMNASMN1; SMN2
SCHEMBL1143474 0.81 CYP1A2 (0.68) CYP1A2CYP2C19MAPK1LMNASMN1; SMN2
SCHEMBL11689824 0.81 CYP1A2 (0.68) CYP1A2CYP2C19MAPK1LMNASMN1; SMN2
SCHEMBL387289 0.81 CYP1A2 (1.00) CYP1A2CYP2C19MAPK1LMNASMN1; SMN2
SCHEMBL4515430 0.81 MAPT (0.60) MAPK1MEN1KMT2AALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3463362-B1 SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS MERCK SHARP & DOHME LLC (US) 2025-09-03 EP disclosed
CN-119661525-A Method for constructing pyrazolo [3,4-b ] pyridine by dehydrocyclization of 5-aminopyrazole and allyl alcohol 润华(江苏)新材料有限公司 2025-03-21 CN disclosed
US-11161819-B2 Substituted tetrahydroisoquinoline compounds useful as GPR120 agonists MERCK SHARP & DOHME CORP. (US) 2021-11-02 US disclosed
US-20200347020-A1 SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS MERCK SHARP & DOHME CORP. (US) 2020-11-05 US disclosed
US-20190161448-A1 SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS MERCK SHARP & DOHME CORP. (US) 2019-05-30 US disclosed
US-10272074-B2 Inhibitors of glucocorticoid receptor translocation Sanford Burnham Prebys Medical Discovery Institute (US) 2019-04-30 US disclosed
US-10272074-B2 Inhibitors of glucocorticoid receptor translocation Sanford Burnham Prebys Medical Discovery Institute (US) 2019-04-30 US disclosed
EP-3463362-A1 SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS Merck Sharp & Dohme Corp. (US) 2019-04-10 EP disclosed
US-10233179-B2 Thiazoles and uses thereof ABBVIE INC. (US) 2019-03-19 US disclosed
US-20180207140-A1 Pyrazolopyrimidines as Inhibitors of Glucocorticoid Receptor Translocation Sanford Burnham Prebys Medical Discovery Institute 2018-07-26 US disclosed
US-8637526-B2 Pyrazolopyrimidine JAK inhibitor compounds and methods GENENTECH, INC. (US) 2014-01-28 US disclosed
WO-2013004617-A1 PYRAZOLOPYRIDINES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM H. LUNDBECK A/S (DK) 2013-01-10 WO disclosed
WO-2013004617-A1 PYRAZOLOPYRIDINES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM H. LUNDBECK A/S (DK) 2013-01-10 WO disclosed
US-20130005743-A1 New positive allosteric modulators of nicotinic acetylcholine receptor H. LUNDBECK A/S (DK) 2013-01-03 US disclosed
US-20130005743-A1 New positive allosteric modulators of nicotinic acetylcholine receptor H. LUNDBECK A/S (DK) 2013-01-03 US disclosed
US-20130005743-A1 New positive allosteric modulators of nicotinic acetylcholine receptor H. LUNDBECK A/S (DK) 2013-01-03 US disclosed
US-6838193-B2 Organic light-emitting diode ACADEMIA SINICA (TW) 2005-01-04 US disclosed
US-20030186082-A1 Organic light-emitting diode TRANSPACIFIC IP LTD. (TW) 2003-10-02 US disclosed
US-4234594-A Pyrazolyl amino imidazolines as antihypertensive agents ABBOTT LABORATORIES (US) 1980-11-18 US disclosed
US-4226773-A Pyrazolyl amino imidazolines as diuretic agents ABBOTT LABORATORIES (US) 1980-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180207140-A1 Pyrazolopyrimidines as Inhibitors of Glucocorticoid Receptor Translocation NR3C1, NR3C2, GRK3 CYP1A2 2328/4885CYP2C19 3447/4885MAPK1 834/4885
US-20190161448-A1 SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS GPR119, GPR88, GPR180 CYP1A2 933/4885CYP2C19 2574/4885MAPK1 1455/4885
US-11161819-B2 Substituted tetrahydroisoquinoline compounds useful as GPR120 agonists GPR119, GPR88, GPR180 CYP1A2 932/4885CYP2C19 2442/4885MAPK1 1495/4885
US-20130005743-A1 New positive allosteric modulators of nicotinic acetylcholine receptor CHRNG, CHRNA7, CHRNA1 CYP1A2 4134/4885CYP2C19 4372/4885MAPK1 2633/4885
US-20200347020-A1 SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS GPR119, GPR88, GPR180 CYP1A2 932/4885CYP2C19 2442/4885MAPK1 1495/4885
US-10233179-B2 Thiazoles and uses thereof SQOR, TXN2, MAVS CYP1A2 3466/4885CYP2C19 3179/4885MAPK1 3101/4885
US-10272074-B2 Inhibitors of glucocorticoid receptor translocation NR3C1, NR3C2, GRK3 CYP1A2 3730/4885CYP2C19 4622/4885MAPK1 1325/4885
US-20030186082-A1 Organic light-emitting diode CRY1, IK, LIG3 CYP1A2 141/4885CYP2C19 95/4885MAPK1 2972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.